Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Other Non-Current Liabilities (2019 - 2021)

Nurix Therapeutics (NRIX) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $796000.0 as the latest value for Q3 2021.

  • On a quarterly basis, Other Non-Current Liabilities fell 8.29% to $796000.0 in Q3 2021 year-over-year; TTM through Aug 2021 was $796000.0, a 8.29% decrease, with the full-year FY2020 number at $850000.0, down 51.07% from a year prior.
  • Other Non-Current Liabilities was $796000.0 for Q3 2021 at Nurix Therapeutics, down from $837000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $1.7 million in Q4 2019 to a low of $796000.0 in Q3 2021.
  • A 3-year average of $986666.7 and a median of $843500.0 in 2020 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 51.07% in 2020, then decreased 8.29% in 2021.
  • Nurix Therapeutics' Other Non-Current Liabilities stood at $1.7 million in 2019, then plummeted by 51.07% to $850000.0 in 2020, then decreased by 6.35% to $796000.0 in 2021.
  • Per Business Quant, the three most recent readings for NRIX's Other Non-Current Liabilities are $796000.0 (Q3 2021), $837000.0 (Q2 2021), and $832000.0 (Q1 2021).